NCT07441928 Effects of Smoking on Network Connectivity in Patients With Schizophrenia Symptoms in Scz Patients
| NCT ID | NCT07441928 |
| Status | Recruiting |
| Phase | — |
| Sponsor | The Hong Kong Polytechnic University |
| Condition | Smoking Cessation |
| Study Type | INTERVENTIONAL |
| Enrollment | 90 participants |
| Start Date | 2023-03-01 |
| Primary Completion | 2026-04-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 90 participants in total. It began in 2023-03-01 with a primary completion date of 2026-04-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The prevalence of smoking among people with schizophrenia (SCZ) is substantially higher at 54% to 90% (McClave et al., 2010). About half of all deaths amongst people with scz are attributed to smoking-related diseases and cancer involving the lung, the cardiovascular system, and the liver (Kely et al., 2011; WHO, 2019). Acceptance and commitment therapy (ACT) is effective for treating psychotic symptoms and addictive behaviours. In a local randomised controlled trial comparing individual ACT to social support for smoking cessation in adult scz smokers, the self-reported quit rates in ACT group were higher than in the social support group (6 months: 12.3% vs. 7.7%, p=0.56 ; 12 months: 10.8% vs. 7.7%, p=0.76; Mak, Loke, and Leung, 2021). In this study, functional neuroimaging (fMRI) will be combined with symptoms assessment in order to ascertain whether group-based ACT is effective in modifying the brain's responses in general and specifically to tobacco craving cues and resting-state functional connectivity in three time points (pre-, post-intervention, and 6-month follow-up) among people with schizophrenia.
Eligibility Criteria
Inclusion Criteria: * Individuals who have been diagnosed with schizophrenia or schizoaffective disorder and after at least one-year followup; * currently taking anti-psychotic medications for ≥ 3 months with good compliance; * aged 18 years or above; * able to communicate in Cantonese Exclusion Criteria: * Have any other current or past psychotic disorders; * with fleeting or actual suicidal/self-harm ideations, or acting-out behavior in the past; * with a known history of violence/aggression and a forensic history * Categorized with special care or intensive care (e.g., arson, battery, physical assault, rape, murder, etc.) * Have a lifetime history of substance abuse and/or are currently receiving treatment for substance abuse (e.g., opioids, cocaine, marijuana, or stimulants); * With alcohol consumption exceeding 25 standard drinks/week for men and 20 standard drinks/week for women over the last 6 months; * Have received a diagnosis of alcohol or drug dependence in the year preceding recruitment; * Are pregnant, breast-feeding, or planning a pregnancy for the duration of the study; * Have a history or current diagnosis of attention-deficit hyperactivity disorder (ADHD); * Have a history of epilepsy or a seizure disorder; * Experience disorientation, have developmental disabilities, and/or an organic mental disorder; * fMRI-related exclusion criteria promulgated by University Research Facility in Behavioural and Systems Neuroscience (UBSN), PolyU
Contact & Investigator
Yim Wah Mak
PRINCIPAL INVESTIGATOR
School of Nursing, The Hong Kong Polytechnic University
Frequently Asked Questions
Who can join the NCT07441928 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Smoking Cessation. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07441928 currently recruiting?
Yes, NCT07441928 is actively recruiting participants. Contact the research team at yw.mak@polyu.edu.hk for enrollment information.
Where is the NCT07441928 trial being conducted?
This trial is being conducted at Hong Kong, Hong Kong, Hong Kong, Hong Kong, Hong Kong, Hong Kong, Hong Kong, Hong Kong and 1 additional location.
Who is sponsoring the NCT07441928 clinical trial?
NCT07441928 is sponsored by The Hong Kong Polytechnic University. The principal investigator is Yim Wah Mak at School of Nursing, The Hong Kong Polytechnic University. The trial plans to enroll 90 participants.